News | July 01, 2025
Briefs: Lyfius Pharma and Aurobindo Pharma
Lyfius Pharma restarts operations at Penicillin-G manufacturing facility
Lyfius Pharma restarts operations at Penicillin-G manufacturing facility
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo
Over 100 million cartridges of rh-insulin supplied to Malaysian health ministry; 345,000+ patients served
The pet dog population alone is expected to increase from 21.4 million in 2019 to 51.5 million by 2028
Granules India receives 1 observation from USFDA for Chantilly facility
The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
Acquisition to be followed by merger; strengthens Torrent’s IPM market presence
The company has been awarded a contract for the supply of essential pharmaceutical formulations to government health institutions across Rajasthan
Eylea 8 mg is the first and only anti-vascular endothelial growth factor (VEGF) treatment in the EU with treatment intervals of up to 6 months for both patients with nAMD and DME
Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts to increase equitable access
Subscribe To Our Newsletter & Stay Updated
